Predictive Value of Vaspin/Tau181 and IMA on Cerebral Edema after Thrombolytic Therapy in Patients with Cerebral Infarction and Analysis of Related Risk Factors

The objective was to investigate the role of Vaspin, Tau181, and IMA in acute cerebral infarction (ACI) and the factors associated with the development of cerebral edema in patients after thrombolytic therapy. One hundred and twenty-three ACI patients who underwent thrombolytic therapy in our hospital from February 2019 to January 2022 (research group) and 106 with healthy physical examination during the same period (control group) were enrolled to this study. The Vaspin, Tau181, and IMA levels in peripheral blood were tested, and the diagnostic value of the three on ACI was analyzed by ROC. The differences in Vaspin, Tau181, and IMA of patients who developed cerebral edema after thrombolytic therapy were then compared with those who did not, and the diagnostic value of the three for disease progression was assessed. Finally, the factors associated with the development of cerebral edema after thrombolytic therapy for ACI was evaluated through logistic regression analysis. In comparison to the control group, Vaspin was lower and Tau181 and IMA were higher in the research group (p < 0.05). All three had superior diagnostic effects for ACI (p < 0.05). In contrast, Vaspin was lower and Tau181 and IMA were higher in patients who developed cerebral edema after thrombolytic therapy (p < 0.05). ROC analysis revealed that all three were also better for diagnosing disease progression (p < 0.05). Logistic regression analysis revealed that leukocytes, NIHSS score, Vaspin, Tau181, and IMA were all independent factors for the development of cerebral edema after thrombolytic therapy for ACI (p < 0.05 Vaspin decreased in ACI, while Tau181 and IMA increased. All three have excellent diagnostic effects on ACI and the occurrence of cerebral edema after thrombolytic therapy, which can assist clinical pairs to accurately understand ACI progression, thus providing a more reliable life safety guarantee for patients.